Home LiteratureArticle Details
PMID: 9769114 Published · ppublish English Journal Article Review

T cell-tumor cell: a fatal interaction?

Cancer immunology, immunotherapy : CII ·Vol. 47 ·No. 2 ·1998-10-00 ·Pages 65-71

Chappell DB, Restifo NP

Abstract

Fas (Apo-1/CD95) is a cell-surface protein that is responsible for initiating a cascade of proteases (caspases) culminating in apoptotic cell death in a variety of cell types. The function of the Fas/FasL system in the dampening of immune responses to infectious agents through the autocrine deletion of activated T cells has been well documented. More recently, it has been proposed that tumor cells express FasL, presumably to avoid immune detection. In this review, we focus on the role of the interaction of Fas and FasL in the modulation of antitumor responses. We critically examine the evidence that FasL is expressed by tumor cells and explore alternative explanations for the observed phenomena in vitro and in vivo. By reviewing data that we have generated in our laboratory as well as reports from the literature, we will argue that the Fas/FasL system is a generalized mechanism used in an autocrine fashion to regulate cell survival and expansion in response to environmental and cellular cues. We propose that FasL expression by tumor cells, when present, is indicative of a perturbed balance in the control of proliferation while "immune privilege" is established by "suicide" of activated antitumor T cells, a form of activation-induced cell death.

MeSH Terms
Animals Apoptosis Cell Communication/physiology Fas Ligand Protein Humans Immunotherapy Lymphocyte Activation Membrane Glycoproteins/biosynthesis,immunology Neoplasms/immunology,pathology,therapy T-Lymphocytes/cytology,immunology fas Receptor/immunology
Chemicals
FASLG protein, human Fas Ligand Protein Membrane Glycoproteins fas Receptor
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Chappell D B
The Howard Hughes Medical Institute-National Institutes of Health Research Scholars Program, Bethesda MD 20814, USA.
Restifo N P
References (54)
54 references, click to expand
  1. The Fas death factor.
    Science. 1995 Mar 10;267(5203):1449-56 PMID: 7533326
  2. TNFalpha regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation.
    Nat Med. 1998 Apr;4(4):415-20 PMID: 9546786
  3. Loss of Fas/Apo-1 receptor accelerates lymphomagenesis in E mu L-MYC transgenic mice but not in animals infected with MoMuLV.
    Oncogene. 1995 Jun 15;10(12):2397-401 PMID: 7784089
  4. Inhibition of ICE family proteases by baculovirus antiapoptotic protein p35.
    Science. 1995 Sep 29;269(5232):1885-8 PMID: 7569933
  5. Fas ligand-induced apoptosis as a mechanism of immune privilege.
    Science. 1995 Nov 17;270(5239):1189-92 PMID: 7502042
  6. Induction of Fas-mediated apoptosis in p53-transfected human colon carcinoma cells.
    Oncogene. 1995 Nov 16;11(10):1939-46 PMID: 7478511
  7. Metalloproteinase-mediated release of human Fas ligand.
    J Exp Med. 1995 Dec 1;182(6):1777-83 PMID: 7500022
  8. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.
    J Natl Cancer Inst. 1996 Jan 17;88(2):100-8 PMID: 8537970
  9. Interfering with apoptosis: Ca(2+)-binding protein ALG-2 and Alzheimer's disease gene ALG-3.
    Science. 1996 Jan 26;271(5248):521-5 PMID: 8560270
  10. Suppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-beta and nitric oxide.
    J Immunol. 1996 Mar 1;156(5):1916-22 PMID: 8596044
  11. Regulation of the Fas lytic pathway in cloned CTL.
    J Immunol. 1996 May 15;156(10):3638-44 PMID: 8621897
  12. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells.
    Nat Med. 1996 May;2(5):574-7 PMID: 8616718
  13. Amelioration of autoimmune reactions by antigen-induced apoptosis of T cells.
    Adv Exp Med Biol. 1995;383:157-66 PMID: 8644500
  14. Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines.
    Cancer Res. 1996 Jun 15;56(12):2832-6 PMID: 8665522
  15. Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL.
    J Exp Med. 1996 Aug 1;184(2):485-92 PMID: 8760802
  16. Human tumor antigens recognized by T lymphocytes: implications for cancer therapy.
    J Leukoc Biol. 1996 Sep;60(3):296-309 PMID: 8830785
  17. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity.
    N Engl J Med. 1996 Nov 28;335(22):1643-9 PMID: 8929361
  18. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape.
    Science. 1996 Nov 22;274(5291):1363-6 PMID: 8910274
  19. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion?
    Nat Med. 1996 Dec;2(12):1361-6 PMID: 8946836
  20. Constitutive Fas ligand expression in several non-lymphoid mouse tissues: implications for immune-protection and cell turnover.
    Behring Inst Mitt. 1996 Oct;(97):156-60 PMID: 8950473
  21. Bcl-x(L) forms an ion channel in synthetic lipid membranes.
    Nature. 1997 Jan 23;385(6614):353-7 PMID: 9002522
  22. Antitumor effect of locally produced CD95 ligand.
    Nat Med. 1997 Feb;3(2):165-70 PMID: 9018234
  23. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53.
    J Clin Invest. 1997 Feb 1;99(3):403-13 PMID: 9022073
  24. Clincal, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis.
    Blood. 1997 Feb 15;89(4):1341-8 PMID: 9028957
  25. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.
    J Exp Med. 1996 Sep 1;184(3):1075-82 PMID: 9064324
  26. Human lung carcinomas express Fas ligand.
    Cancer Res. 1997 Mar 15;57(6):1007-12 PMID: 9067260
  27. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?
    J Clin Invest. 1997 Mar 15;99(6):1173-8 PMID: 9077524
  28. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors.
    Nature. 1997 Apr 3;386(6624):517-21 PMID: 9087414
  29. The molecular regulation of lymphocyte apoptosis.
    Semin Immunol. 1997 Feb;9(1):1-5 PMID: 9106302
  30. The role of the Caspase family of cysteine proteases in apoptosis.
    Semin Immunol. 1997 Feb;9(1):35-49 PMID: 9106306
  31. The CD95 system and the death of a lymphocyte.
    Semin Immunol. 1997 Feb;9(1):59-68 PMID: 9106308
  32. Cancer vaccines based on the identification of genes encoding cancer regression antigens.
    Immunol Today. 1997 Apr;18(4):175-82 PMID: 9136454
  33. Radiation and stress-induced apoptosis: a role for Fas/Fas ligand interactions.
    Proc Natl Acad Sci U S A. 1997 May 27;94(11):5750-5 PMID: 9159145
  34. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas.
    Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6420-5 PMID: 9177233
  35. Reversal of tumor-induced immunosuppression: a new approach to cancer therapy.
    J Immunother. 1997 May;20(3):165-77 PMID: 9181454
  36. Fas and other cell death signaling pathways.
    Semin Immunol. 1997 Apr;9(2):93-107 PMID: 9194220
  37. Double identity for proteins of the Bcl-2 family.
    Nature. 1997 Jun 19;387(6635):773-6 PMID: 9194558
  38. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction.
    Nat Med. 1997 Jul;3(7):738-43 PMID: 9212099
  39. Inhibition of death receptor signals by cellular FLIP.
    Nature. 1997 Jul 10;388(6638):190-5 PMID: 9217161
  40. Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors.
    Brain Pathol. 1997 Jul;7(3):863-9 PMID: 9217971
  41. Thymineless death in colon carcinoma cells is mediated via fas signaling.
    Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8144-9 PMID: 9223329
  42. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3.
    Cell. 1997 Aug 8;90(3):405-13 PMID: 9267021
  43. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma.
    J Exp Med. 1997 Aug 29;186(5):785-93 PMID: 9271594
  44. Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis.
    J Immunol. 1997 Oct 15;159(8):3808-15 PMID: 9378968
  45. Maintenance of clonotype specificity in CD95/Apo-1/Fas-mediated apoptosis of mature T lymphocytes.
    J Immunol. 1997 Oct 15;159(8):3816-22 PMID: 9378969
  46. Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis.
    Science. 1997 Nov 14;278(5341):1305-9 PMID: 9360929
  47. Mutations in the Fas antigen in patients with multiple myeloma.
    Blood. 1997 Dec 1;90(11):4266-70 PMID: 9373236
  48. A Myc-induced apoptosis pathway surfaces.
    Science. 1997 Nov 14;278(5341):1246-7 PMID: 9411752
  49. Immune response and myoblasts that express Fas ligand.
    Science. 1997 Nov 14;278(5341):1322-4 PMID: 9411754
  50. Gene transfer of Fas ligand induces tumor regression in vivo.
    Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13862-7 PMID: 9391118
  51. Downregulation of Fas ligand by shedding.
    Nat Med. 1998 Jan;4(1):31-6 PMID: 9427603
  52. Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis.
    Cancer Res. 1998 Feb 1;58(3):526-34 PMID: 9458101
  53. The duration of antigenic stimulation determines the fate of naive and effector T cells.
    Immunity. 1998 Jan;8(1):89-95 PMID: 9462514
  54. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome.
    Cell. 1995 Jun 16;81(6):935-46 PMID: 7540117
Article Info
Journal
Cancer immunology, immunotherapy : CII
Abbr.
Cancer Immunol Immunother
ISSN
0340-7004
Published
1998-10-00
Pages
65-71
Language
English
Region
Germany
NLM ID
8605732
PMCID
PMC2249694
Subset
IM
Grants
Intramural NIH HHS · Z01 BC010763-01 · United States
Intramural NIH HHS · Z99 CA999999 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com